CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AbCellera Biologics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AbCellera Biologics Inc
2215 Yukon Street
Phone: (604) 559-9005p:604 559-9005 Vancouver, BC  V5Y 0A1  Canada Ticker: ABCLABCL
Business Summary
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer, Co-Founder Carl L.Hansen 49 11/1/2012 11/1/2012
Co-Founder, Chief Operating Officer, Director VeroniqueLecault 39 1/1/2019 8/1/2018
Chief Financial Officer AndrewBooth 50 8/1/2019 6/1/2016
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Trianni, Inc. 1515 5th Avenue San Francisco CA United States

Business Names
Business Name
AbCellera Properties Inc.
AbCellera Quebec Inc. Canada Lineage Biosciences Inc. Delaware Trianni Inc.
ABCL
4 additional Business Names available in full report.

General Information
Number of Employees: 586 (As of 12/31/2023)
Outstanding Shares: 295,366,280 (As of 10/31/2024)
Shareholders: 75
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024